NovaBridge Biosciences Files 6-K for ESMO IO Poster Release
Ticker: NBP · Form: 6-K · Filed: Dec 10, 2025 · CIK: 1778016
Sentiment: neutral
Topics: disclosure, conference-presentation, press-release
TL;DR
NovaBridge Biosciences filed a 6-K on 12/10/25 for an ESMO IO poster, but details are in the press release.
AI Summary
On December 10, 2025, NovaBridge Biosciences filed a Form 6-K to report the issuance of a press release regarding an ESMO IO poster presentation. The filing itself does not contain the details of the press release content, only that it was issued.
Why It Matters
This filing indicates NovaBridge Biosciences is actively participating in scientific conferences, suggesting ongoing research and development efforts that could impact future drug development.
Risk Assessment
Risk Level: low — The filing is a routine disclosure of a press release and does not contain new financial or operational information that would immediately impact risk.
Key Players & Entities
- NovaBridge Biosciences (company) — Filer of the 6-K
- December 10, 2025 (date) — Date of press release issuance
- ESMO IO (event) — Conference mentioned in the press release
FAQ
What is the specific content of the press release mentioned in the 6-K?
The 6-K filing states that NovaBridge Biosciences issued a press release on December 10, 2025, regarding an ESMO IO poster presentation, but the content of the press release is not included in this Form 6-K.
When was this Form 6-K filed?
This Form 6-K was filed on December 10, 2025.
What is the primary purpose of a Form 6-K filing?
A Form 6-K is a report of foreign private issuers pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934, typically used to furnish information that the issuer has made or is about to make public in its home country.
What is the SIC code for NovaBridge Biosciences?
The Standard Industrial Classification (SIC) code for NovaBridge Biosciences is 2834, which corresponds to Pharmaceutical Preparations.
Has NovaBridge Biosciences changed its name previously?
Yes, the company was formerly known as I-Mab, with a date of name change on May 28, 2019.
Filing Stats: 208 words · 1 min read · ~1 pages · Grade level 13.2 · Accepted 2025-12-10 16:37:05
Filing Documents
- pr_-_esmo_io_poster_-_12.htm (6-K) — 29KB
- nbp-ex99_1.htm (EX-99.1) — 62KB
- nbp-ex99_2.htm (EX-99.2) — 1KB
- img62529193_0.jpg (GRAPHIC) — 440KB
- img63452714_0.jpg (GRAPHIC) — 7085KB
- 0001193125-25-314328.txt ( ) — 10456KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. NovaBridge Biosciences By : /s/ Xi-Yong Fu Name : Xi-Yong (Sean) Fu Title : Chief Executive Officer Date: December 10, 2025